Editorial commentary: step on the GAS: are we almost there for clindamycin and intravenous immunoglobulin?
Section of Infectious Diseases and Immunity, Imperial College London, United Kingdom.
Lionel K K
LK
Tan
Section of Infectious Diseases and Immunity, Imperial College London, United Kingdom.
Shiranee
S
Sriskandan
D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D002981:Clindamycin / Q000627:therapeutic use*; D019115:Fasciitis, Necrotizing; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use*; D013290:Streptococcal Infections / Q000188:drug therapy; D013297:Streptococcus pyogenes
D000900:Anti-Bacterial Agents; D016756:Immunoglobulins, Intravenous; D002981:Clindamycin
clindamycin; immunoglobulin; mortality; necrotizing fasciitis; streptococcal